| Original language | English (US) |
|---|---|
| Pages (from-to) | 141-144 |
| Number of pages | 4 |
| Journal | JAMA Internal Medicine |
| Volume | 180 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2020 |
ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies among US Medicare Beneficiaries between 2012 and 2017. / Sumarsono, Andrew; Everett, Brendan M.; McGuire, Darren K.; Fonarow, Gregg C.; Butler, Javed; Pandey, Ambarish; Vaduganathan, Muthiah.
In: JAMA Internal Medicine, Vol. 180, No. 1, 01.2020, p. 141-144.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies among US Medicare Beneficiaries between 2012 and 2017
AU - Sumarsono, Andrew
AU - Everett, Brendan M.
AU - McGuire, Darren K.
AU - Fonarow, Gregg C.
AU - Butler, Javed
AU - Pandey, Ambarish
AU - Vaduganathan, Muthiah
N1 - Funding Information: Author Contributions: Drs Sumarsono and Vaduganathan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sumarsono, Butler, Pandey, Vaduganathan. Acquisition, analysis, or interpretation of data: Sumarsono, Everett, McGuire, Fonarow, Butler, Vaduganathan. Drafting of the manuscript: Sumarsono, Butler, Vaduganathan. Critical revision of the manuscript for important intellectual content: All authors. Study supervision: Butler, Pandey, Vaduganathan. Conflict of Interest Disclosures: Dr Everett reports receiving grant support and/or consulting for Amarin, Amgen, Merck, Novartis, and Roche Diagnostics, the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and the US Food and Drug Administration. Dr McGuire reports honoraria for trial leadership from Astra Zeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, Esperion, Lilly US; and honoraria for consulting for Astra Zeneca, Sanofi Aventis, Lilly US, Astra Zeneca, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Metavant, and Applied Therapeutics. Dr Fonarow reports significant consulting for Novartis, and modest consulting for Abbott, Amgen, Bayer, Janssen, and Medtronic. Dr Butler has received research support from the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and the European Union; and serves as a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. Dr Pandey is supported by the Texas Health Resources Clinical Scholars Program. Dr Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, and Boehringer Ingelheim, and participates on clinical end point committees for studies sponsored by Novartis and the NIH. No other conflicts are reported.
PY - 2020/1
Y1 - 2020/1
UR - http://www.scopus.com/inward/record.url?scp=85072785627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072785627&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2019.3884
DO - 10.1001/jamainternmed.2019.3884
M3 - Letter
C2 - 31566649
AN - SCOPUS:85072785627
VL - 180
SP - 141
EP - 144
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 1
ER -